Literature DB >> 21958221

Double-plating of ovine critical sized defects of the tibia: a low morbidity model enabling continuous in vivo monitoring of bone healing.

Joachim A Hahn1, Tanja S Witte, Daniel Arens, Alexandra Pearce, Simon Pearce.   

Abstract

BACKGROUND: Recent studies using sheep critical sized defect models to test tissue engineered products report high morbidity and complications rates. This study evaluates a large bone defect model in the sheep tibia, stabilized with two, a novel Carbon fibre Poly-ether-ether-ketone (CF-PEEK) and a locking compression plate (LCP) which could sustain duration for up to 6 month with an acceptable low complication rate.
METHODS: A large bone defect of 3 cm was performed in the mid diaphysis of the right tibia in 33 sheep. The defect was stabilised with the CF - PEEK plate and an LCP. All sheep were supported with slings for 8 weeks after surgery. The study was carried out for 3 months in 6 and for 6 months in 27 animals.
RESULTS: The surgical procedure could easily be performed in all sheep and continuous in vivo radiographic evaluation of the defect was possible. This long bone critical sized defect model shows with 6.1% a low rate of complications compared with numbers mentioned in the literature.
CONCLUSIONS: This experimental animal model could serve as a standard model in comparative research. A well defined standard model would reduce the number of experimental animals needed in future studies and would therefore add to ethical considerations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958221      PMCID: PMC3195802          DOI: 10.1186/1471-2474-12-214

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  16 in total

Review 1.  Cell culture methods for testing biocompatibility.

Authors:  A Pizzoferrato; G Ciapetti; S Stea; E Cenni; C R Arciola; D Granchi; L Savarino
Journal:  Clin Mater       Date:  1994

Review 2.  Bone graft and bone graft substitutes: a review of current technology and applications.

Authors:  C J Damien; J R Parsons
Journal:  J Appl Biomater       Date:  1991

3.  The influence of hydroxyapatite granules on the healing of a segmental defect filled with autologous bone marrow.

Authors:  B Wippermann; C Donow; H E Schratt; F C den Boer; T Blokhuis; P Patka
Journal:  Ann Chir Gynaecol       Date:  1999

4.  Healing of segmental bone defects with granular porous hydroxyapatite augmented with recombinant human osteogenic protein-1 or autologous bone marrow.

Authors:  Frank C den Boer; Burkhard W Wippermann; Taco J Blokhuis; Peter Patka; Fred C Bakker; Henk J Th M Haarman
Journal:  J Orthop Res       Date:  2003-05       Impact factor: 3.494

5.  Morbidity at bone graft donor sites.

Authors:  E M Younger; M W Chapman
Journal:  J Orthop Trauma       Date:  1989       Impact factor: 2.512

6.  Enhanced healing of segmental tibial defects in sheep by a composite bone substitute composed of tricalcium phosphate cylinder, bone morphogenetic protein, and type IV collagen.

Authors:  T J Gao; T S Lindholm; B Kommonen; P Ragni; A Paronzini; T C Lindholm; T Jämsä; P Jalovaara
Journal:  J Biomed Mater Res       Date:  1996-12

7.  [Importance of cell cultures in biocompatible dental materials research].

Authors:  Mohebbian Nahid; Peter Bottenberg
Journal:  Rev Belge Med Dent (1984)       Date:  2003

8.  The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects.

Authors:  S D Cook; G C Baffes; M W Wolfe; T K Sampath; D C Rueger; T S Whitecloud
Journal:  J Bone Joint Surg Am       Date:  1994-06       Impact factor: 5.284

9.  Effects of one-plane and two-plane external fixation on sheep osteotomy healing and complications.

Authors:  Gert D Krischak; Andreas Janousek; Steffen Wolf; Peter Augat; Lothar Kinzl; Lutz E Claes
Journal:  Clin Biomech (Bristol, Avon)       Date:  2002-07       Impact factor: 2.063

10.  The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats.

Authors:  A W Yasko; J M Lane; E J Fellinger; V Rosen; J M Wozney; E A Wang
Journal:  J Bone Joint Surg Am       Date:  1992-06       Impact factor: 5.284

View more
  6 in total

1.  Ovine model for critical-size tibial segmental defects.

Authors:  Chris Christou; Rema A Oliver; Matthew H Pelletier; William R Walsh
Journal:  Comp Med       Date:  2014-10       Impact factor: 0.982

2.  A preclinical large-animal model for the assessment of critical-size load-bearing bone defect reconstruction.

Authors:  David S Sparks; Siamak Saifzadeh; Flavia Medeiros Savi; Constantin E Dlaska; Arne Berner; Jan Henkel; Johannes C Reichert; Martin Wullschleger; Jiongyu Ren; Amaia Cipitria; Jacqui A McGovern; Roland Steck; Michael Wagels; Maria Ann Woodruff; Michael A Schuetz; Dietmar W Hutmacher
Journal:  Nat Protoc       Date:  2020-02-14       Impact factor: 13.491

3.  The preclinical sheep model of high tibial osteotomy relating basic science to the clinics: standards, techniques and pitfalls.

Authors:  Dietrich Pape; Henning Madry
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-07-21       Impact factor: 4.342

4.  Angle-stable interlocking nailing in a canine critical-sized femoral defect model for bone regeneration studies: In pursuit of the principle of the 3R's.

Authors:  W B Saunders; L M Dejardin; E V Soltys-Niemann; C N Kaulfus; B M Eichelberger; L K Dobson; B R Weeks; S C Kerwin; C A Gregory
Journal:  Front Bioeng Biotechnol       Date:  2022-09-02

5.  A low morbidity surgical approach to the sheep femoral trochlea.

Authors:  Patrick Orth; Henning Madry
Journal:  BMC Musculoskelet Disord       Date:  2013-01-03       Impact factor: 2.362

6.  New aspects on efficient anticoagulation and antiplatelet strategies in sheep.

Authors:  Annika Weigand; Anja M Boos; Jürgen Ringwald; Maren Mieth; Ulrich Kneser; Andreas Arkudas; Oliver Bleiziffer; Dorothee Klumpp; Raymund E Horch; Justus P Beier
Journal:  BMC Vet Res       Date:  2013-10-03       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.